Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
68.55
-0.02 (-0.03%)
At close: Jun 18, 2026, 4:00 PM EDT
68.61
+0.06 (0.09%)
After-hours: Jun 18, 2026, 6:20 PM EDT
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Halozyme Therapeutics stock has a consensus rating of "Buy" and an average price target of $83.9. The average 1-year stock price forecast is 22.39% higher than the current stock price, while the lowest is $57 (-16.85%) and the highest is $96 (+40.04%).
Price Target: $83.9 (+22.39%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Halozyme Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 9 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $95 | Buy | Reiterates | $95 | +38.58% | Jun 16, 2026 |
| Goldman Sachs | Goldman Sachs | Sell Maintains $57 | Sell | Maintains | $57 | -16.85% | Jun 15, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $93 | Buy | Maintains | $93 | +35.67% | Jun 15, 2026 |
| Wells Fargo | Wells Fargo | Hold Reiterates $75 | Hold | Reiterates | $75 | +9.41% | Jun 15, 2026 |
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains $70 | Hold | Maintains | $70 | +2.12% | May 20, 2026 |
Financial Forecast
Revenue This Year
1.78B
from 1.40B
Increased by 27.27%
Revenue Next Year
2.00B
from 1.78B
Increased by 12.47%
EPS This Year
8.14
from 4.15
Increased by 96.17%
EPS Next Year
9.89
from 8.14
Increased by 21.52%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.8B | ||
| Avg | 1.8B | ||
| Low | 1.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 29.7% | ||
| Avg | 27.3% | ||
| Low | 25.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.21 | ||
| Avg | 8.14 | ||
| Low | 8.04 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 97.8% | ||
| Avg | 96.2% | ||
| Low | 93.7% |